SC 13D/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

 

 

Merus N.V.

(Name of Issuer)

Common Shares, nominal value €0.09 per share

(Title of Class of Securities)

N5749R100

(CUSIP Number)

Peter Haahr

Novo Holdings A/S

Tuborg Havnevej 19

Hellerup, Denmark DK-2900

+45 3527 6592

Copy to:

B. Shayne Kennedy, Esq.

Latham & Watkins LLP

650 Town Center Drive, 20th Floor

Costa Mesa, CA 92626

Telephone: (714) 540-1235

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 24, 2018

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.    ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

 

 

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No.: N5749R100

 

  1.   

Name of Reporting Person:

 

Novo Holdings A/S

  2.  

Check the Appropriate Box if a Member of Group (See Instructions):

 

(a)  ☐        (b)  ☒

  3.  

SEC Use Only:

 

  4.  

Source of Funds:

 

WC

  5.  

Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

 

  6.  

Citizenship or Place of Organization:

 

Denmark

Number of

Shares

Beneficially

Owned By

Each

Reporting

Person

With:

 

     7.    

Sole Voting Power:

 

1,102,795

     8.   

Shared Voting Power:

 

0

     9.   

Sole Dispositive Power:

 

1,102,795

   10.   

Shared Dispositive Power:

 

0

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person:

 

1,102,795

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares:

 

13.  

Percent of Class Represented By Amount In Row (11):

 

4.88% (1)

14.  

Type of Reporting Person:

 

CO

 

(1) Based upon 22,620,635 Common Shares outstanding as of March 31, 2018, reported in the Issuer’s Form F-3 Registration Statement filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2018.

 

2


This amendment (“Amendment No. 4”) amends the Schedule 13D originally filed with the SEC on May 26, 2016, as subsequently amended by Amendment No. 1 filed with the SEC on June 2, 2016, by Amendment No. 2 filed with the SEC on March 3, 2017 and by Amendment No. 3 filed with the SEC on July 20, 2017 (collectively, the “Schedule”). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule.

Item 2. Identity and Background

Item 2 of the Schedule is amended and replaced in its entirety as follows for the purpose of updating the directors and executive officers of Novo Holdings A/S and the Foundation listed on Schedule I:

 

  (a) The reporting person (“Reporting Person”) is Novo Holdings A/S, a Danish limited liability company that is wholly owned by Novo Nordisk Fonden (the “Foundation”), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S, Novozymes A/S and NNIT A/S) and is responsible for managing the Foundation’s assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.

The name of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on Schedule I to this Amendment No. 4.

 

  (b) The business address of both Novo Holdings A/S and the Foundation is Tuborg Havnevej 19, 2900 Hellerup, Denmark.

The residence or business address of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on Schedule I to this Amendment No. 4.

 

  (c) Novo Holdings A/S, a holding company that is responsible for managing the Foundation’s assets, provides seed and venture capital to development stage companies and invests in well-established companies within the life science and biotechnology sector.

The Foundation is a Danish self-governing and profit-making foundation, whose objectives are to provide a stable basis for commercial and research activities undertaken by the group of Novo companies and to support scientific, humanitarian and social purposes through grants.

 

  (d) Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in Schedule I has been convicted in any criminal proceedings.

 

  (e) Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in Schedule I was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

3


Item 5. Interest in Securities of the Issuer

Item 5(a) of the Schedule is amended and replaced in its entirety as follows:

(a) Novo Holdings A/S beneficially owns 1,102,795 Common Shares (the “Novo Shares”), representing approximately 4.88% of the Issuer’s outstanding Common Shares, based upon 22,620,635 Common Shares outstanding as of March 31, 2018, as reported in the Issuer’s F-3 Registration Statement filed with the SEC on May 15, 2018.

Item 5(b) of the Schedule is amended and replaced in its entirety as follows:

(b) Novo Holdings A/S is a Danish limited liability company wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S, through its Board of Directors (the “Novo Board”), has the sole power to vote and dispose of the Novo Shares. The Novo Board, currently comprised of Lars Rebien Sorensen, Steen Riisgaard, Francis Cuss, Jean-Luc Butel, Jeppe Christiansen and Viviane Monges, may exercise voting and dispositive control over the Novo Shares only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Novo Shares. Except as described in this Amendment No. 4, neither the Foundation nor any person listed on Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

Item 5(c) of the Schedule is supplemented as follows:

(c) On July 19, 2018, Novo Holdings A/S sold 2,712 shares of the Issuer’s Common Shares in the open market through a broker’s transaction at a weighted average price of $24.026 per share.

On July 23, 2018, Novo Holdings A/S sold 4,910 shares of the Issuer’s Common Shares in the open market through a broker’s transaction at a weighted average price of $23.0479 per share.

On July 24, 2018, Novo Holdings A/S sold 300,000 shares of the Issuer’s Common Shares in a block trade at a price of $21.00 per share.

Item 5(e) of the Schedule is amended and replaced in its entirety, as follows:

(e) The Reporting Person ceased to be a beneficial owner of 5% or more of the Issuer’s Common Shares on July 24, 2018.

 

4


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: July 27, 2018   

Novo Holdings A/S

 

/s/ Peter Haahr

By: Peter Haahr

Its: Chief Financial Officer


Schedule I

Information regarding each director and executive officer of both Novo Holdings A/S and the Novo Nordisk Foundation is set forth below.

 

Novo Holdings A/S

Name, Title

  

Address

  

Principal Occupation

  

Citizenship

Lars Rebien Sørensen,
Chairman of the Board
   Søllerødvej 83, Søllerød
2840 Holte
Denmark
   Professional Board Director    Denmark
Steen Riisgaard,
Vice Chairman of the Board
   Hestetangsvej 155,
3520 Farum,
Denmark
   Professional Board Director    Denmark
Jean-Luc Butel,
Director
   235 Arcadia Road, #03-04, 28984 Singapore    Global Healthcare Advisor, President, K8 Global Pte Ltd.    France
Jeppe Christiansen,
Director
   Kollemosevej 37,
2830 Virum,
Denmark
   Chief Executive Officer,
Fondsmaeglerselskabet Maj Invest A/S
   Denmark
Francis Cuss,
Director
   111 Rippling Brook Way,
Bernardsville,
NJ 07924
USA
   Former Executive Vice President and Chief Scientific Officer of Bristol-Myers Squibb    United Kingdom

Viviane Monges,

Director

   Chemin de Craivavers 32, 1012 Lausanne, Switzerland    Professional Board Director    France

Kasim Kutay,

Chief Executive Officer of Holdings A/S

   Bredgade 63, 3.th. 1260 Copenhagen K. Denmark    Chief Executive Officer of Novo Holdings A/S    United Kingdom

Peter Haahr,

Chief Financial Officer of Novo Holdings A/S

   Ordrup Have 21
2900 Charlottenlund
Denmark
   Chief Financial Officer of Novo Holdings A/S    Denmark

Thomas Dyrberg,

Managing Partner Novo Ventures

   Bengtasvej 9a
2900 Hellerup
Denmark
   Managing Partner –Ventures, Novo Holdings A/S    Denmark

Michael Shalmi,

Managing Partner

Principal Investments

  

Stigårdsvej 4, 2900 Hellerup

Denmark

   Head of Principal Investments, Novo Holdings A/S    Denmark

Dorte Barlebo Madsen,

Head of People & Organisation

   Hoffmeyersvej 13
2000 Frederiksberg
Denmark
   Head of People & Organisation, Novo Holdings A/S    Denmark

Morten Beck Jørgensen,

Managing Director, Financial Investments

   Ellesøpark 20, 2950 Vedbæk
Denmark
   Managing Director, Novo Holdings A/S Financial Investments    Denmark


Novo Holdings A/S

Name, Title

  

Address

  

Principal Occupation

  

Citizenship

Søren Møller,
Managing Partner, Novo Seeds
   Ved Furesøen 9
2840 Holte
Denmark
   Managing Partner, Novo Seeds, Novo Holdings A/S    Denmark

 

Novo Nordisk Foundation

Name, Title

  

Address

  

Principal Occupation

  

Citizenship

Lars Rebien Sørensen,

Chairman of the Board

  

Søllerødvej 83, Søllerød

2840 Holte

Denmark

   Professional Board Director    Denmark

Marianne Philip,

Vice Chairman of the Board

  

Tranegårdsvej 5

2900 Hellerup

Denmark

   Attorney    Denmark

Steen Riisgaard,

Director

   Hestetangsvej 155
3520 Farum
Denmark
   Professional Board Director    Denmark

Birgitte Nauntofte,

Chief Executive Officer

  

Engbakkevej 24
2920 Charlottenlund

Denmark

   Chief Executive Officer, Novo Nordisk Foundation    Denmark

Anne Marie Kverneland,

Director

  

Nybrovej 216

2800 Kgs. Lyngby

Denmark

   Laboratory technician, Novo Nordisk A/S    Denmark

Lars Bo Køppler,

Director

  

Anemonevej 7

3550 Slangerup

Denmark

   Technician, Novozymes A/S    Denmark

Lars Fugger,

Director

   72 Staunton Road, Headington
OX3 7TP
Great Britain
   Professor, John Radcliffe Hospital, University of Oxford, Oxford, Great Britain    Denmark

Lars Henrik Munch,

Director

  

Galionsvej 46

1437 København K

Denmark

   Professional Board Director    Denmark

Mads Boritz Grøn,

Director

  

Horsevænget 4

3400 Hillerød

Denmark

   Senior Lead Auditor    Denmark

Liselotte Højgaard,

Director

  

Grønningen 21

1270 København K

Denmark

   Professor    Denmark